Phase 1 clinical trial of WRAIR-developed COVID-19 vaccine begins

(Walter Reed Army Institute of Research) A unique vaccine to protect against COVID-19 begins clinical testing Tuesday, 6 April, at WRAIR. Scientists developed a nanoparticle vaccine, based on a ferritin platform, which offers a flexible approach to targeting multiple variants of SARS-COV-2 and potentially other coronaviruses as well. This platform is the next generation vaccine, one that paves the way for a universal vaccine to protect against not only the current virus, but also counter future ...